Molecular relapse can be detected in blood in a sensitive and timely fashion in B-lineage acute lymphoblastic leukemia TO 
THE EDITOR
The use of peripheral blood to detect and quantify minimal residual disease (MRD) in leukemia has practical and, possibly, theoretical advantages over the use of marrow. Obtaining blood is simple and pain free and its use enables monitoring at relatively frequent intervals. It is also possible that samples of blood are not subject to sampling error which occurs with samples of marrow. 1 MRD can be detected and quantified in peripheral blood either by the polymerase chain reaction (PCR) 2 or by immunophenotyping. 3 Since rising levels of disease can be demonstrated in bone marrow prior to clinical relapse, 4, 5 we decided to determine whether rising levels could likewise be detected in the blood by PCR and whether the features of such molecular relapse in blood were such as to suggest that monitoring of blood may be of practical value. If answers to these questions were in the affirmative, then this would indicate that more extensive prospective studies of the value of monitoring of blood could well be important.
Eight patients with B-lineage acute lymphoblastic leukemia (ALL) were selected who had a relapse involving marrow, the same monoclonal immunoglobulin heavy chain (IgH) or T cell receptor chain (TCR␥) gene rearrangement which was present at diagnosis and relapse and for which quantification was technically possible, and at least one blood sample adequate for study which had been obtained within the 6 months prior to relapse. MRD was quantified by PCR as previously described 6, 7 and the absolute number of leukemic cells per liter of blood was calculated by multiplying together the leukocyte count and the relative MRD level. The eight patients comprised three children, two adolescents and three adults; six were studied during the period prior to the first relapse and two during the period prior to the second relapse. MRD was detected prior to relapse in all of the eight patients and the results are shown in Figure 1 . Levels of leukemia were 10 4 -10 6 cells/liter when first detected and rose to approximately 10 9 -10 11 cells/liter at relapse. In seven of the eight patients the number of leukemic cells increased approximately exponentially during the 8-10 weeks prior to relapse. Approximate doubling times were between 1.6 and 5.2 days. The eighth patient had a level of approximately 3 × 10 8 blasts/liter at clinical relapse and a similar value in the single pre-relapse sample available several weeks beforehand. MRD was detected in all patients at least 10 weeks prior to relapse and in one patient 24 weeks prior to relapse.
For seven of the eight patients the level of leukemia at the time of detection of molecular relapse was approximately five orders of magnitude less than the level at the time of clinical relapse. This would suggest that in these patients the total body burden of leukemic cells at the time of molecular relapse was correspondingly lower. For ALL at diagnosis it is known that the total number of leukemic cells present, as estimated from levels of blasts in the blood, is an important determinant of cure by chemotherapy. Detection of molecular relapse, when the body burden of leukemia is low, may enable treatment to be instituted at this time and it may be more effective than treatment instituted at the time of clinical relapse. Leukemia was also detected at a substantial time prior to clinical relapse. Our ability to detect leukemia at an early time was limited by size and availability of samples but, nevertheless, in the four patients with the longest series of samples, leukemia was detected at 19, 21, 23 and 24 weeks prior to relapse. With respect to treatment, this observation suggests that molecular relapse can be identified sufficiently early so that there is time to either confirm detection or demonstrate a rising level of leukemia, so that treatment can be instituted in a timely fashion. Careful attention to sample volume and timing might enable even earlier detection of molecular relapse and at a lower level of MRD. With the exception of one patient, for whom there was only one sample available prior to relapse, the MRD levels showed a fairly rapid rate of increase in the 4-6 weeks prior to relapse. Approximate doubling times ranged from 1.6 to 5.2 days, with a median of 2-3 days. This rate of increase is much greater than that which can be inferred for childhood leukemia prior to diagnosis, 8 but it is similar to the rate of increase observed in marrow for childhood leukemia relapsing during treatment. 5 It seems likely that leukemia at relapse represents a rapidly growing subclone which, by extrapolation, in our patients had arisen approximately 5 months previously.
We previously reported data suggesting that the leukemic population at diagnosis consists of a major subpopulation which is drugsensitive and a minor subpopulation which is relatively drug-resistant. 9 We speculated that for patients destined to relapse, the critical mutations responsible for the phenotype of complete drug resistance most often occurred prior to diagnosis and led to the presence of a completely resistant clone within the larger relatively drug-resistant subpopulation. Nevertheless, irrespective of when the completely resistant clone arises, the cells which comprise it will persist and undergo further mutation, epimutation and selection during subsequent treatment, largely owing to the mutagenic and selective effects of chemotherapy. One can predict that this would lead to repeated clonal succession and the final emergence of a rapidly expanding clone, as was observed in the present study. If detection of molecular relapse in blood eventually proves to require detection of the ultimate rapidly-expanding clone, then, for practical reasons related to sampling and confirmation, the interval between confirmed molecular relapse and overt clinical relapse may be brief and, the knowledge that molecular relapse is present may be of little clinical value. On the other hand, if confirmation of molecular relapse can be based on the detection of slowly expanding earlier clones, then the interval may be much longer and clinically useful information may be obtained.
This study is, of course, only the first step in determining the utility of monitoring MRD in peripheral blood in order to detect molecular relapse. The next step will involve one or more large prospective studies, aimed at determining the general feasibility of the use of blood in a variety of patient subsets and at determining clinical outcomes, both in patients in whom the level of MRD is rising and in patients in whom MRD either is not detected or appears to be stable. Since
Figure 1
The number of leukemic cells in blood prior to clinical relapse in eight patients. Blasts were quantitated by PCR for all pre-relapse samples, and by a differential count for relapse samples. Each line represents one patient. Closed circles represent samples in which MRD was detected and quantified; open circles represent samples in which MRD was not detected in blood, but for which an upper limit could be calculated.
any prospective study will, of necessity, use the gene rearrangement of the clone which is predominant at diagnosis, there will undoubtedly be a proportion of patients in whom MRD is not detected, owing to clonal evolution, but yet who relapse. Finally, even if monitoring of blood to detect molecular relapse is shown to have adequate positive and negative predictive value, the efficacy of treatment based on such monitoring will need to be established. The development of simpler methods for quantifying MRD will greatly facilitate such future studies.
